(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 15.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.03%.
Genmab A's revenue in 2026 is $3,720,000,000.On average, 23 Wall Street analysts forecast GMAB's revenue for 2026 to be $276,096,677,584, with the lowest GMAB revenue forecast at $197,533,104,600, and the highest GMAB revenue forecast at $302,305,948,048. On average, 19 Wall Street analysts forecast GMAB's revenue for 2027 to be $315,539,060,096, with the lowest GMAB revenue forecast at $231,836,414,472, and the highest GMAB revenue forecast at $346,501,972,752.
In 2028, GMAB is forecast to generate $369,242,369,184 in revenue, with the lowest revenue forecast at $328,129,788,064 and the highest revenue forecast at $415,879,453,392.